IRIS
BALLABENI, Vigilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.939
EU - Europa 6.412
AS - Asia 6.139
SA - Sud America 1.001
AF - Africa 335
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 5
Totale 25.856
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.673
SG - Singapore 2.421
CN - Cina 2.259
FI - Finlandia 1.261
SE - Svezia 1.058
IE - Irlanda 940
BR - Brasile 804
DE - Germania 747
UA - Ucraina 697
IT - Italia 688
HK - Hong Kong 491
VN - Vietnam 376
GB - Regno Unito 246
TR - Turchia 230
NL - Olanda 227
ZA - Sudafrica 202
CA - Canada 172
RU - Federazione Russa 122
FR - Francia 103
IN - India 94
AR - Argentina 73
BE - Belgio 69
BD - Bangladesh 57
CI - Costa d'Avorio 57
AT - Austria 56
MX - Messico 53
RO - Romania 46
IQ - Iraq 35
CZ - Repubblica Ceca 34
EC - Ecuador 34
ES - Italia 34
ID - Indonesia 33
JP - Giappone 31
PL - Polonia 26
CM - Camerun 25
EU - Europa 24
KR - Corea 22
CO - Colombia 21
VE - Venezuela 19
PK - Pakistan 17
PY - Paraguay 17
MA - Marocco 16
LT - Lituania 12
PA - Panama 12
PE - Perù 11
AZ - Azerbaigian 9
TN - Tunisia 9
CL - Cile 8
CR - Costa Rica 8
UZ - Uzbekistan 8
EG - Egitto 7
NP - Nepal 7
BG - Bulgaria 6
BO - Bolivia 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
DO - Repubblica Dominicana 5
EE - Estonia 5
KE - Kenya 5
KZ - Kazakistan 5
MY - Malesia 5
UY - Uruguay 5
AU - Australia 4
DK - Danimarca 4
JM - Giamaica 4
LB - Libano 4
PT - Portogallo 4
SC - Seychelles 4
SI - Slovenia 4
AL - Albania 3
BY - Bielorussia 3
DZ - Algeria 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
NI - Nicaragua 3
PH - Filippine 3
RS - Serbia 3
SA - Arabia Saudita 3
SV - El Salvador 3
BB - Barbados 2
BN - Brunei Darussalam 2
CH - Svizzera 2
GY - Guiana 2
HN - Honduras 2
HR - Croazia 2
MD - Moldavia 2
NG - Nigeria 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
IM - Isola di Man 1
IS - Islanda 1
Totale 25.848
Salva come PNG Salva come JPEG
Città #
Dallas 4.206
Singapore 1.258
Dublin 939
Ashburn 928
Chandler 911
Jacksonville 744
Santa Clara 584
Beijing 558
Hong Kong 490
Dearborn 450
Ann Arbor 448
Boardman 311
Nanjing 244
New York 199
Izmir 195
Johannesburg 195
Parma 189
Munich 182
Princeton 179
Shanghai 168
Ho Chi Minh City 160
Los Angeles 156
San Mateo 132
Wilmington 127
Hefei 124
Toronto 110
Helsinki 102
Bremen 88
Hebei 83
Kunming 78
Jinan 75
Nanchang 75
Shenyang 75
Hanoi 73
Moscow 70
São Paulo 69
Brussels 66
Grafing 64
Buffalo 63
Abidjan 57
Woodbridge 55
Tianjin 52
Guangzhou 51
Turku 51
Chicago 48
Vienna 48
Changsha 44
Columbus 43
Des Moines 43
London 36
Seattle 34
Brooklyn 32
Tokyo 31
Frankfurt am Main 30
Rio de Janeiro 28
Fremont 27
Jiaxing 27
Council Bluffs 25
Auburn Hills 24
Bologna 24
Montreal 24
Milan 23
Norwalk 23
The Dalles 23
Hangzhou 22
Pune 22
Houston 21
San Jose 21
Warsaw 21
Marseille 20
Zhengzhou 20
West Jordan 19
Belo Horizonte 18
Amsterdam 17
Bengaluru 17
Boston 17
Brno 17
Lubbock 17
Redondo Beach 17
Stockholm 17
Atlanta 16
Brasília 16
Phoenix 16
Jakarta 15
Nuremberg 15
San Francisco 15
Taiyuan 15
Chennai 14
Denver 14
Haiphong 14
Ottawa 14
Campinas 13
Curitiba 13
Düsseldorf 13
Fuzhou 13
Haikou 13
Seoul 13
Ankara 12
Lanzhou 12
Manchester 12
Totale 16.652
Salva come PNG Salva come JPEG
Nome #
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.641
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.639
1,5-Benzodiazepin tricyclic derivatives as analgersic, anti-inflammatory and /or antipyretic agents with very low acute gastrolesivity and toxicity 1.577
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 217
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 209
2-Aminobenzimidazoles as new potent H3-antagonists 198
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 191
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 188
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 183
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 176
Aminobenzimidazoles as new potent H3-antagonists 172
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 169
Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil 167
Protective Effects of a Protease Inhibitor (Gabexate Mesilate) on Intestinal Ischemia/Reperfusion Injury in Rats 165
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 163
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 162
Caratterizzazione farmacologica in vitro di nuovi agonisti muscarinici analoghi dell'Oxotremorina 161
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 161
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 161
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 160
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 160
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 159
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 159
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 157
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 156
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 152
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 152
Adaptive changes in rat ileum motility induced by mild mesenteric ischemia/reperfusion injury: role of endogenous mediators and reperfusion time 151
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 151
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 149
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 148
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 147
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 145
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 144
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 144
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 143
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 142
Regional differences in motor responsiveness to antimuscarinic drugs in rabbit isolated small and large intestine 140
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 140
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 138
Analgesici-antipiretici benzopirano pirimidinici non acidici attivi per via orale privi di gastrolesività 138
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 137
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 137
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae. 136
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 135
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 133
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 133
Nuovi potenti agonisti muscarinici oxotremorina-M simili a struttura acetilenica: studio funzionale in vitro 133
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 133
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 131
Motor responses of rat hypertrophic intestine following chronic obstruction 131
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 130
Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity 128
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 128
CNS access of selected H3-antagonists: ex vivo binding study in rats 127
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 127
Functional Studies of New Imidazole H3-Antagonists on Guinea-Pig Isolated Preparations 127
Influence of Nitric Oxide system in mesenteric ischemia-reperfusion induced injury in mice 127
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 127
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 126
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 125
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 125
Radiological analysis of gastrointestinal dysmotility associated with central dopaminergic impairment in an animal model of parkinson's disease (PD) 125
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 125
Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats 125
Preliminary study of calcium balance and bone mineralization improvement by a new calcium supplement in growing rats 124
R-a-methylhistamine-induced inhibition of gastric acid secretion in pylorus-ligated rats via central histamine H3 receptors 123
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 122
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 121
Different role of the Histamine H3 Receptor in Vagal-, Betanechol-, Pentagastrin-induced Gastric Acid Secretion in Anaesthetized Rats 121
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 120
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 120
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 119
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae 119
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 117
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 117
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 117
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 117
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 117
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 117
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 117
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 116
Role of Glutamate- N-methyl-D-Aspartate (NMDA) Receptors in Neuronal Plasticity and Gastrointestinal Transit Delay Induced by Ischemia/Reperfusion in Rats 116
Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: preliminary pharmacological investigation. 116
Distinct Roles of α4β2 and α7 Nicotinic Receptors in the Modulation of Inflammatory Responses in TNBS-Induced Colitis 116
The selective inhibition of inducible nitric oxide synthase prevents intestinal ischemia-reperfusion injury in mice 115
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 115
Synthesis and pharmacological screening of novel non-acidic gastric-sparing antiinflammatory/antiplatelet agents:5-alkyl/cycloalkylamino substituted 2-amino-5H-[1]benzopyrano[4,3-d]pyrimidines 115
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 114
Proteinase-Activated Receptor 2 agonist prevents mesenteric ischemia/reperfusion injury in rats: partila involvement of Substance P (SP) and Calcitonin-Gene Related Peptide (CGRP) 109
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 109
Involvement of 5-HT2A receptors in motor and inflammatory disorders induced by mesenteric ischemia reperfusion in mice 108
PHENYLPROPANOID RICH ESSENTIAL OILS AS POTENTIAL ANTITHROMBOTICS ENDOWED WITH GASTROPROTECTIVE EFFECTS 108
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 108
Pharmacological modulation of 5HT1A receptors in mice mesenteric ischemia/reperfusion injury: protective effect of Buspirone and WAY100135 107
Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice 107
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 107
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 106
Synthesis and functional characterization of novel heterocyclic derivatives related to oxotremorine and oxotremorine-M 106
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 106
Totale 18.098
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021841 0 0 0 0 0 52 183 19 292 47 211 37
2021/20221.034 24 30 25 111 62 85 121 136 41 65 77 257
2022/20233.734 445 375 229 259 385 411 71 213 1.124 40 121 61
2023/20241.332 81 106 45 52 106 348 115 67 49 74 95 194
2024/20254.199 122 227 295 225 367 499 144 182 468 412 362 896
2025/20269.179 880 1.680 3.915 958 1.250 496 0 0 0 0 0 0
Totale 25.993